FDA-cleared profile

Rapid

iSchema View Inc. · Radiological images; modality varies or is not specified in FDA list · FDA-cleared (510(k))

Authorized purpose: Rapid is image-viewing, processing, and analysis software for DICOM CT, CT perfusion, CT angiography, C-arm CT perfusion, and MRI data, including perfusion maps and acute-stroke selection support under the labeled occlusion and imaging criteria.

Clinical role
Multimodality image viewing, perfusion analysis, reporting, and acute-stroke workflow support.
Images and patients
Radiological images; modality varies or is not specified in FDA list · Brain, cerebral vasculature, and perfusion regions
Key limitation
Keep in mind: The FDA labeling limits use to adults and supported imaging criteria. Inadequate bolus, motion, hemorrhage, and other exclusions require professional assessment; C-arm CT perfusion is qualitative and is not for thrombectomy selection.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Rapid is image-viewing, processing, and analysis software for DICOM CT, CT perfusion, CT angiography, C-arm CT perfusion, and MRI data, including perfusion maps and acute-stroke selection support under the labeled occlusion and imaging criteria.
  • Which images or clinical context are in scope?Modality: Radiological images; modality varies or is not specified in FDA list Anatomy or clinical context: Brain, cerebral vasculature, and perfusion regions Input: DICOM CT, CT perfusion, CT angiography, C-arm CT perfusion, and MRI data including diffusion-weighted and dynamic studies.
  • Who uses it?Intended users: Trained professionals, including physicians and medical technicians.
  • What does the software produce?Output: Images, perfusion maps, tissue-flow and blood-volume values, mismatch and volumetric analyses, reports, and C-arm perfusion qualitative results.
  • What is its most important limitation?Key limitation: The FDA labeling limits use to adults and supported imaging criteria. Inadequate bolus, motion, hemorrhage, and other exclusions require professional assessment; C-arm CT perfusion is qualitative and is not for thrombectomy selection.

Clinical takeaway. Clinical role: Rapid is image-viewing, processing, and analysis software for DICOM CT, CT perfusion, CT angiography, C-arm CT perfusion, and MRI data, including perfusion maps and acute-stroke selection support under the labeled occlusion and imaging criteria.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports phantom validation testing characterizing perfusion imaging performance on conventional CT and C-arm CT scanners, stating accurate representation of key processing parameters under clinically relevant parameters and perturbations, and comparable conventional CT and C-arm CT results with small biases in MTT and Tmax expected from temporal resolution differences; it also reports software verification and validation meeting all design requirements and specifications, and validation through phantoms and case data. Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Rapid is image-viewing, processing, and analysis software for DICOM CT, CT perfusion, CT angiography, C-arm CT perfusion, and MRI data, including perfusion maps and acute-stroke selection support under the labeled occlusion and imaging criteria.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Multimodality image viewing, perfusion analysis, reporting, and acute-stroke workflow support.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
DICOM CT, CT perfusion, CT angiography, C-arm CT perfusion, and MRI data including diffusion-weighted and dynamic studies.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Images, perfusion maps, tissue-flow and blood-volume values, mismatch and volumetric analyses, reports, and C-arm perfusion qualitative results.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Hospital stroke and angiography-suite workflows.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Trained professionals, including physicians and medical technicians.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
The FDA labeling limits use to adults and supported imaging criteria. Inadequate bolus, motion, hemorrhage, and other exclusions require professional assessment; C-arm CT perfusion is qualitative and is not for thrombectomy selection.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports phantom validation testing characterizing perfusion imaging performance on conventional CT and C-arm CT scanners, stating accurate representation of key processing parameters under clinically relevant parameters and perturbations, and comparable conventional CT and C-arm CT results with small biases in MTT and Tmax expected from temporal resolution differences; it also reports software verification and validation meeting all design requirements and specifications, and validation through phantoms and case data. Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "iSchemaView conducted extensive phantom validation testing of the Rapid System for characterizing the perfusion imaging performance of conventional CT and C-arm CT scanners." … "The performance validation testing demonstrated that the Rapid system provides accurate representation of key processing parameters under a range of clinically relevant parameters and perturbations associated with the intended use of the software.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports phantom validation testing characterizing perfusion imaging performance on conventional CT and C-arm CT scanners, stating accurate representation of key processing parameters under clinically relevant parameters and perturbations, and comparable conventional CT and C-arm CT results with small biases in MTT and Tmax expected from temporal resolution differences; it also reports software verification and validation meeting all design requirements and specifications, and validation through phantoms and case data. Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "iSchemaView conducted extensive phantom validation testing of the Rapid System for characterizing the perfusion imaging performance of conventional CT and C-arm CT scanners." … "The performance validation testing demonstrated that the Rapid system provides accurate representation of key processing parameters under a range of clinically relevant parameters and perturbations associated with the intended use of the software.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-04

Do not generalize an endpoint across populations, thresholds, versions, or workflows; use only exact evidence.metrics records.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

K233582 FDA evidence package for Rapid

  • DesignFDA 510(k) decision evidence and product verification for the exact submission.
  • PopulationBrain, cerebral vasculature, and perfusion regions
  • Scopeexact submission
  • Tested versionRapid
  • IndependenceSponsor or vendor study

K233582

FDA-submitted evidence for the exact decision; it is not independent clinical validation and does not establish local production qualification.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
No record matched K233582 by exact native submission identifier in the 2026-09-02 openFDA snapshot; this does not exclude product-family, later-version, or adverse-event information.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-04
Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

No product-specific code

No exact-product reimbursement determination identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

This public-policy review is not a coverage determination. Verify payer, site-of-service, coding, and local value assumptions independently.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM CT, CT perfusion, CT angiography, C-arm CT perfusion, and MRI data including diffusion-weighted and dynamic studies.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA 510(k) decision material K233582: Rapid

  2. Routing

    Source context, not route validation: The FDA package describes DICOM data received from files, media, or network sources and processed by a Rapid Server connected to the hospital LAN or firewall.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-04 · FDA 510(k) decision material K233582: Rapid

  3. AI processing

    Source context, not route validation: The FDA package describes a dedicated or virtual Rapid Server on a standard computer or VMware virtual platform; current hosting, security, availability, and local routing remain unknown.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-04 · FDA 510(k) decision material K233582: Rapid

  4. Returned objects

    Source context, not route validation: Images, perfusion maps, tissue-flow and blood-volume values, mismatch and volumetric analyses, reports, and C-arm perfusion qualitative results.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA 510(k) decision material K233582: Rapid

  5. Viewer/worklist/report

    Unresolved route: Images, perfusion maps, tissue-flow and blood-volume values, mismatch and volumetric analyses, reports, and C-arm perfusion qualitative results.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA 510(k) decision material K233582: Rapid

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The FDA package describes a dedicated or virtual Rapid Server on a standard computer or VMware virtual platform; current hosting, security, availability, and local routing remain unknown.
  • Exact FDA submission
  • Checked 2026-09-04
Integration
The FDA package describes DICOM data received from files, media, or network sources and processed by a Rapid Server connected to the hospital LAN or firewall.
  • Exact FDA submission
  • Checked 2026-09-04
Security
RapidAI's current platform security and compliance one-pager states that its portfolio uses encryption at rest and in transit, role-based access control, monitoring/logging and listed HIPAA, GDPR, ISO 13485, ISO 27001, ISO 27701 and SOC 2 Type 1 claims.
  • Vendor-wide
  • Checked 2026-10-25

This is a current vendor-wide statement, not an independent attestation for the exact K223396 release; site-specific architecture, retention, contractual scope and current certification evidence remain unestablished.

Training
Use by trained professionals, including physicians and medical technicians. Follow the exact labeling, local training, supervision, and escalation requirements.
  • Exact FDA submission
  • Checked 2026-09-04
Monitoring
Monitor labeled population, acquisition quality, exclusions, reviewer overrides, failures, and downstream workflow effects for K233582.
  • Exact FDA submission
  • Checked 2026-09-04

Release and scope verification

Map installed build, options, population, anatomy, inputs, outputs, and enabled functions to K233582.

exact submission · checked 2026-09-04

Deployment boundary

The FDA package describes a dedicated or virtual Rapid Server on a standard computer or VMware virtual platform; current hosting, security, availability, and local routing remain unknown.

exact submission · checked 2026-09-04

Interoperability acceptance

The FDA package describes DICOM data received from files, media, or network sources and processed by a Rapid Server connected to the hospital LAN or firewall.

exact submission · checked 2026-09-04

Clinical acceptance

Test labeled population, acquisition quality, exclusions, failed inputs, reviewer overrides, and downstream effects for K233582.

exact submission · checked 2026-09-04

Economic evaluation

Exact-product price, implementation cost, reimbursement, and total-cost evidence remain to be obtained; do not infer them from FDA clearance.

product family · checked 2026-09-04

Lifecycle monitoring

Monitor labeling, software version, complaints, recalls, failed inputs, overrides, and postmarket signals against the exact submission and installed configuration.

exact submission · checked 2026-09-04
Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K233582
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Radiological images; modality varies or is not specified in FDA list
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Brain, cerebral vasculature, and perfusion regions
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2024-04-22
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Human reviewedStatus
2026-09-04Last searched
27Fields reviewed
12Source classes checked
20Screened PubMed leads
10Screened trial leads
0Unreviewed FDA recall leads

No evidence was promoted. All records use rapid as a generic word or concern unrelated diseases, methods, or interventions; none identifies the Rapid imaging product, tested version, or K233582. The current discovery snapshot contains 20 PubMed and 10 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor security document, fda decision material, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public list price or commercial contract for the exact submission and version was identified.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No exact-product payer coverage or reimbursement determination was identified in reviewed public material.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

8 sources - 3 history items

Source ledger

  1. FDA 510(k) decision material K233582: Rapid

    U.S. Food and Drug Administration - Published 2024-04-22 - Accessed 2026-09-04

    Scope: identity, submission_linkage, modality, anatomy, clinical_use, intended_users, care_setting, workflow_role, input, output, limitations, evidence

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Rapid model card (K233582)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  8. RapidAI security and compliance one-pager

    RapidAI - Accessed 2026-09-08

    Scope: vendorWideSecurity, deployment, implementationCapabilities

Research history

  1. K233582 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    human reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K250831

Annalise Enterprise

Annalise-AI

Authorized purpose: Triage and prioritization of adult CXR and non-contrast brain CT studies for specified suspected findings, including pneumoperitoneum, pleural effusion, pneumothorax and tension pneumothorax on CXR, and acute extra-axial hemorrhage, subarachnoid hemorrhage, intra-axial hemorrhage, intraventricular hemorrhage, mass effect, obstructive hydrocephalus and vasogenic edema on brain CT.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Chest/Lung; Brain
Decision
2025-04-23
FDA-cleared K233512

Rapid (6.0)

iSchemaView, Inc.

Authorized purpose: Rapid Platform v6.0 is image-processing software for trained professionals that views, processes, and analyzes DICOM images from CT and MRI. It supports functional and dynamic datasets including CT perfusion, CT angiography, diffusion-weighted MRI, and dynamic contrast-enhanced CT or MRI, with maps and measurements for tissue perfusion, diffusion, and blood volume. Rapid CT-Perfusion and Rapid MR-Perfusion may aid physicians in selecting acute stroke patients with known occlusion of the intracranial internal carotid artery or proximal middle cerebral artery for endovascular thrombectomy, subject to the labeled imaging criteria, clinical requirements, and exclusions.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain and intracranial vessels represented in CT perfusion, CTA, and MRI; tissue perfusion, diffusion, and contrast dynamics
Decision
2024-01-16
FDA-cleared K213165

Rapid

iSchema View Inc.

Authorized purpose: Rapid processes CT, CTP, CTA, diffusion MRI, and dynamic-contrast MRI for stroke viewing, perfusion, volumetry, mismatch, and large-vessel-density support for trained professionals.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain
Decision
2022-02-08
FDA-cleared K200750

Neuro.Al Algorithm

TeraRecon, Inc.

Authorized purpose: Neuro.Al Algorithm processes static, functional, dynamic, and derived CT or MR images to support brain perfusion analysis, tissue blood-volume and parametric-map review, ventricular visualization, and DICOM return to clinical viewers for trained professional interpretation.

Modality
Radiological images; modality varies or is not specified in FDA list
Anatomy
Brain and intracranial perfusion regions
Decision
2020-11-06

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history